| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Basic Science: Therapy, Metrics & InterventionTherapy, Metrics & Intervention Posters |
1 Nuclear Medicine, U.T. M.D. Anderson Cancer Center, Houston, Texas; 2 Radio-diagnosis, National Cancer Institute, Cairo, Egypt
1421
Objectives: To evaluate the outcomes of patients receiving Y-90 SIR Spheres(SS) in patients with multiple liver metastases from different tumors.
Methods: 29 consecutive patients with multiple liver metastases from colorectal (13), neuroendocrine (8), pancreatic (5) or non-small cell lung cancer (3) who were treated with Y-90 SS between March, 2003 and February, 2006 were included. Only patients who had follow-up radiological exams at our institution were included. Data regarding Y-90 SS dose, lobe of liver treated, and chemotherapy (CTx) administered were collected. Patients’ outcomes were evaluated based on radiological evidence of change in size and number of liver metastases.
Results: The study population included 8 females and 21 males at a mean age of 60y. The mean Y-90 SS dose administered was 36.2 +/- 12.6 mCi. Both lobes of the liver, the right lobe only or the left lobe only were treated in 26, 2, 1 patients, respectively. Sixteen patients received Y-90 SS after CTx failure, 5 patients as adjuvant therapy after completion of CTx and 7 patients as concurrent therapy. One patient refused repeat CTx. The mean interval between the last CTx and Y-90 SS was 109 +/- 117days. Four patients (14%) demonstrated radiological improvement and 9 (31%) were stable for a mean interval of 2.8 mo. after Y-90 SS infusion. Sixteen patients (55%) demonstrated continued progress of liver metastases.
Conclusions: Y-90 SS therapy is useful in reducing or stabilizing multiple liver metastases from a variety of tumors.
| ||||||||||||||||||||||||||||||||||||||
